# A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System

Study · id `cardio:ct-nct04179045` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04179045](<https://clinicaltrials.gov/study/NCT04179045>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04179045

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 785 participants.

## Technical summary

Registry record NCT04179045. Allocation not applicable; no masking; primary purpose treatment. Start 2021-03-01 (anticipated); primary completion 2022-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 785 participants (planned count; ClinicalTrials.gov record NCT04179045, source copy `cardio:ctgov-nct04179045-2021-02-26`, retrieved 2026-10-26)
- Planned start: 2021-03-01 (anticipated) (ClinicalTrials.gov record NCT04179045, source copy `cardio:ctgov-nct04179045-2021-02-26`, retrieved 2026-10-26)
- Primary completion: 2022-07 (anticipated) (ClinicalTrials.gov record NCT04179045, source copy `cardio:ctgov-nct04179045-2021-02-26`, retrieved 2026-10-26)
- Completion: 2026-07 (anticipated) (ClinicalTrials.gov record NCT04179045, source copy `cardio:ctgov-nct04179045-2021-02-26`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04179045, source copy `cardio:ctgov-nct04179045-2021-02-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04179045-2021-02-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Condition: Coronary Artery Disease
- Intervention (Device): The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Lead sponsor: Shanghai Bio-heart Biological Technology Co., Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: CCRF Inc., Beijing, China
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as a collaborator: CCRF Inc., Beijing, China (`cardio:org-ccrf-inc-beijing-china`)

## Provenance

Content hash: 16d740ecccfc1b87df54a86c536a13ef58c3523df2115559aa545985f9ad9bb8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
